HLA-A*01:01 (Monomer) protein (DSG3)
Origin: Human
Host: HEK-293 Cells
Recombinant
> 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
-
- Target
- HLA-A*01:01
- Protein Type
- Recombinant
- Protein Characteristics
- Monomer
- Origin
- Human
-
Source
- HEK-293 Cells
- Purification tag / Conjugate
- DSG3
- Purpose
- Human HLA-A*01:01 & B2M & DSG3 (YTDNWLAVY) Monomer Protein
- Sequence
- Gly25-Thr305 (HLA-A*01:01), Ile21-Met119 (B2M) and YTDNWLAVY peptide.
- Specificity
- Uni-Prot: Q5SUL5 (HLA-A*01:01), P61769 (B2M), YTDNWLAVY
- Characteristics
- Recombinant Human HLA-A*01:01 & B2M & DSG3 (YTDNWLAVY) Monomer Protein is expressed from HEK293 with His tag and Avi Tag at the C-Terminus.It contains Gly25-Thr305(HLA-A*01:01), Ile21-Met119(B2M) and YTDNWLAVY peptide..
- Purity
- > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
- Sterility
- 0.22 μm filtered
- Endotoxin Level
- Less than 1EU per μg by the LAL method.
-
-
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in distilled water.
- Buffer
- Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.
- Storage
- -20 °C,-80 °C
- Storage Comment
- -20 to -80°C for 12 months as supplied from date of receipt.,-80°C for 3-6 months after reconstitution.,2-8°C for 2-7 days after reconstitution.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Expiry Date
- 12 months
-
- Target
- HLA-A*01:01
- Background
- DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. DSG3 is identified overexpressed in HNC, with the degree of overexpression associated with clinicopathologic features of the tumor. Inhibition of DSG3 significantly suppresses carcinogenic potential in cellular and in vivo animal studies. These findings suggest that DSG3 is a potential molecular target in the development of adjuvant therapy for HNC.
- Molecular Weight
- 50.50 kDa. Due to glycosylation, the protein migrates to 52-62 kDa based on Tris-Bis PAGE result.
- UniProt
- Q5SUL5
-
You are here:
